AbbVie
0.34 %
9.05 %
Yet to be announced
Company Overview
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism.
Revenue Sources
PassBased on AbbVie's financial reports and SEC filings, the company's revenue is primarily derived from the development and sale of pharmaceutical products and treatments. These activities are considered halal as they provide legitimate medical benefits and contribute to human health and wellbeing. There is no evidence of significant revenue from prohibited sources such as alcohol, gambling, or other haram activities.
Reliance on Interest
| Reporting Date | Total Revenue | Total Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Dec. 31, 2024 | $15.1b | $16.59b | - | - | 0.00% | 0.00% |
| Sept. 30, 2024 | $14.46b | $10.63b | - | - | 0.00% | 0.00% |
| June 30, 2024 | $14.46b | $10.46b | - | - | 0.00% | 0.00% |
| March 31, 2024 | $12.31b | $9.51b | - | - | 0.00% | 0.00% |
Analysis of AbbVie's financial statements over the past four quarters shows no reported interest income or interest expense in their operational results. The company's revenue is primarily derived from its core pharmaceutical business operations.
Operational Ethics
PassBased on the company's public disclosures and available information, while AbbVie operates globally, there is no evidence of significant ongoing collaboration with entities involved in human rights violations. The company maintains standard business operations in various countries but no direct material ties to problematic regimes have been identified.
Comments